Highlights Santhera Pharmaceuticals Holding AG

Equities

SANN

CH1276028821

Market Closed - Swiss Exchange Other stock markets 11:30:42 2024-05-31 am EDT			5-day change	1st Jan Change
9.87 ^CHF	-1.30%		+5.45%	+0.61%

Apr. 25	Transcript : Santhera Pharmaceuticals Holding AG, 2023 Earnings Call, Apr 25, 2024
Apr. 25	Santhera Pharmaceuticals Swings to Profit in FY23; Revenue Grows	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Santhera Pharmaceuticals Swings to Profit in FY23; Revenue Grows	Apr. 25	MT
Santhera Pharmaceuticals Holding AG Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 25	CI
Santhera Pharmaceuticals Terminates Cystic Fibrosis Drug License Deal with Spexis	Apr. 17	MT
Santhera Announces NDA for Vamorolone in Duchenne Muscular Dystrophy Accepted and Grants Priority Review by China's NMPA	Mar. 27	CI
Catalyst Pharmaceuticals Announces Publication of Santhera Pharmaceutical?s VISION-DMD Vamorolone (AGAMREE®) Study Results in the Peer-Reviewed Journal Neurology	Feb. 21	CI
Santhera Pharmaceuticals Holding AG Launches AGAMREE in Germany as First Market for the Treatment of Duchenne Muscular Dystrophy	Jan. 15	CI
Santhera Pharmaceuticals Obtains UK Approval for Duchenne Muscular Dystrophy Treatment	Jan. 12	MT
Santhera Pharmaceuticals Receives U.S. FDA Approval of Agamree(R) for the Treatment of Duchenne Muscular Dystrophy	23-10-27	CI
US FDA approves Santhera's drug for rare muscular dystrophy	23-10-26	RE
US FDA approves Santhera's Duschenne drug	23-10-26	RE
Santhera Pharmaceuticals Receives Positive CHMP Opinion Recommending Approval of AGAMREE®? for the Treatment of Duchenne Muscular Dystrophy	23-10-13	CI
Santhera Pharmaceuticals Narrows H1 Attributable Loss; Revenue Down	23-09-07	MT
Santhera Pharmaceuticals Holding AG Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-07	CI
Santhera Pharmaceuticals Closes Sale of Idebenone Business to Italy's Chiesi Farmaceutici	23-07-31	MT
Chiesi Farmaceutici S.p.A. acquired Raxone®/idebenone business worldwide from Santhera Pharmaceuticals Holding AG.	23-07-30	CI
Santhera Grants Catalyst Pharmaceuticals Licensing Rights in North America for Vamorolone	23-07-19	MT
Reverse Split: 1 of 10	23-07-02	FA
Catalyst to License Rights to Santhera's Dissociative Steroid Vamorolone in North America	23-06-20	MT
Catalyst Pharmaceuticals to License North American Rights to Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals	23-06-20	CI
Santhera Pharmaceuticals Signs $231 Million US Licensing Deal for Duchenne Muscular Dystrophy Drug	23-06-20	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Santhera Pharmaceuticals Holding AG

Equities

SANN

CH1276028821

Highlights

Filters